UC Office of the President

Recent Work

Title

Managing the Adaptive Proteostatic Landscape: Restoring Resilience in Alpha-1 Antitrypsin Deficiency

Permalink

<https://escholarship.org/uc/item/6q11f7hq>

Authors

Wang, Chao
Balch, William E

Publication Date

2016

DOI

10.1007/978-3-319-23449-6_4

Peer reviewed

Chapter 4

Managing the Adaptive Proteostatic Landscape: Restoring Resilience in Alpha-1 Antitrypsin Deficiency

Chao Wang and William E. Balch

Abbreviations

PN	Proteostasis network
ER	Endoplasmic reticulum
AAT	Alpha-1 antitrypsin
Q-state	Quinary state
APL	Adaptive proteostatic landscape
AATD	Alpha-1 antitrypsin deficiency
NE	Neutrophil elastase
COPD	Chronic obstructive pulmonary disease
RCL	Reactive center loop
WT	Wild-type
COPII	Coatomer protein complex II
G/ERAD	Glycan ER-associated degradation
ER-phagy	ER-associated autophagy response
BAL	Bronchoalveolar lavage
HSR	Heat shock response
UPR	Unfolded protein response
MSR	Maladaptive stress response

C. Wang • W.E. Balch (✉)

Department of Chemical Physiology, The Skaggs Institute for Chemical Biology,
The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, San Diego,
CA 92037, USA

e-mail: chaowang@scripps.edu; webalch@scripps.edu

© Springer International Publishing Switzerland 2016

A. Wanner, R.S. Sandhaus (eds.), *Alpha-1 Antitrypsin*, Respiratory Medicine,
DOI 10.1007/978-3-319-23449-6_4

53

ERAF	ER-assisted folding and glycosylation
QC	Quality control
NEF	Nucleotide exchange factors
HAT	Histone acetyltransferase
HDAC	Histone deacetylase
HDACi	Histone deacetylase inhibitor

Protein nascent chains emerging from the ribosome generate a native conformation through multiple folding pathways and diverse energetic intermediates, defined by a funnel-like folding energy landscape that shapes protein function in the cytosol and endomembrane trafficking pathways [1–7]. It is now recognized that “folded” proteins also dynamically fluctuate among different energetic states [8, 9] and ~30 % eukaryotic proteins can be disordered transiently or permanently at different times in their functional lifespan [10–13]. De novo folding and local conformational interconversions in vivo are particularly challenging to the cellular folding program and prone to misfold and aggregate in the complex intra- [12, 14] and extracellular [15–17] environments unless protected.

To address multiple folding challenges defined in the inherited genome, biology has evolved a sophisticated program, referred to as *proteostasis* [5, 6, 18–25], which faithfully manages protein structure and the multiplicity of dynamic native conformations required to fulfill function in response to diverse signals stemming from complex cell, tissue, and organismal demands. This proteostasis program is an evolutionarily ancient system [19] that integrates protein synthesis, folding, degradation, and membrane trafficking systems including both the exocytic [endoplasmic reticulum (ER), Golgi, cell surface] and endocytic (endosomes, lysosome) pathways harboring alpha-1 antitrypsin (AAT) [26–28]. The proteostasis network (PN) generates a buffer that can be used to form a “cloud” around each energetic folding species that functions as capacitor to define the dynamic “quinary state (Q-state)” of protein fold [19, 26, 29–31]. The Q-state encompasses the highly dynamic non-covalent ionic, hydrogen bonding, hydrophobic, and van der Waals surface forces responsible for all biology. It responds to reversible covalent modifications such as acetylation–deacetylation and ubiquitin modifications of surface Lys residues and facilitates integration of the more structurally ordered secondary, tertiary, and quaternary states encoded by the primary sequence to define the structural and functional properties of the protein fold. In response to Q-state properties, PN components can regulate the multiple conformations defining the energetic states of each folding species and also determine the turnover and intra-/extracellular location of each folding species. The PN contributes to a complex and dynamic in vivo structural and functional landscape of folding proteome, referred as the *adaptive proteostatic landscape* (APL) (Fig. 4.1). Modulating the composition, concentration, and/or function of PN components remodels the APL, hence regulating the function of folding proteome in response to folding stress—both acute and chronic as occurs in inherited or evolving environmental-triggered disease [6, 30, 32–36]. APL provides a novel

Fig. 4.1 A schematic diagram of APL. A protein adopts numerous energetic states illustrated here in a folding energy landscape with several states highlighted, such as folding intermediate (*I*), native state (*N*), misfolded state (*M*), and aggregate state (*A*). These states fluctuate among multiple local energy minima. The PN recognizes these folding species harboring different thermodynamic and kinetic properties to define the Q-states and hence determines the functional environment (the Anfinsen physiological state) of each folding species. Here, a general “cloud” is used to represent the Q-state, but since the folding energy constantly changes, the Q-state likely also changes along the folding landscape, which is shown as a color scale from *cyan* to *red*. The conversion between Q-states and/or the turnover of folding species is highly dynamic and largely affected by both the PN and global stresses. Thus, modulating PN components could rebalance the APL from the stressed/diseased state to healthy state. HSR, heat shock response; UPR, unfolded protein response

therapeutic paradigm for all protein misfolding diseases [18, 20, 26, 30, 37] including *alpha-1 antitrypsin deficiency* (AATD) [23, 27, 38], which will be explored in this chapter.

AATD in the Context of Proteostasis Network

AATD is a consequence of point mutations produced in the inherited AAT gene [39–43]. AAT, which is mainly synthesized by hepatocytes, is the key antiprotease in serum that prevents the degradation of lung tissues by neutrophil elastase (NE) [40, 44–46]. The most common mutation triggering AATD is the Z-variant (Glu342Lys), which affects about 1 in 1600–3000 live births [47, 48]. We will primarily use this mutation to discuss the role of the PN in managing AATD, points which will equally apply to other AATD disease mutations [39, 40].

The Z-mutation alters the protein folding energetics of AAT. It produces misfolded and aggregated AAT that triggers serial responses from the PN, which differentially manages the APL in both the liver and lung in its attempt to maintain a healthy proteome for optimum biological activity [23, 27, 38], but sometimes fails [30]. When the capacity of PN is challenged in the liver, the increased polymerization/aggregation of misfolded AAT in the ER of hepatocytes leads to neonatal hepatitis [49], cirrhosis [50], and hepatocellular carcinoma [40, 51, 52]. On the other hand, the decreased pool of functional circulating plasma AAT [53] disrupts the protease–antiprotease balance in the lung and causes chronic obstructive pulmonary disease (COPD) and/or emphysema [27, 54–56].

In this review, we will first describe the proteostasis stress challenge in AATD and how the PN responds to the problem in the liver–plasma–lung axis. We will then discuss the rationale for therapeutically managing the APL by modulating the PN to mitigate folding stress and restore Z-AAT functionality and, finally, describe new potential therapeutic efforts by directly targeting the operational properties of the PN that are applicable to AATD.

The Folding Stress-Responsive APL in the Liver of AATD

Hepatocytes continuously synthesize and secrete a large amount of AAT to maintain a steady-state concentration range of 20–48 μM in serum [41]. To achieve a functional, folded form that can traverse the exocytic pathway, the newly synthesized AAT polypeptide chain needs to fold into a three-dimensional structure in the ER. Studies of the folding mechanisms of purified AAT *in vitro* revealed an intermediate folding state (*I*) between the unfolded state (*U*) and native state (*N*) (Fig. 4.2a), which is prone to misfold and polymerize [40–42, 57–62]. Furthermore, the native conformation of AAT is kinetically trapped in a metastable conformation with reactive center loop (RCL) transitioning through disordered and ordered conformational states during the AAT functional cycle [63, 64]. Therefore, the polymorphic intermediate state and the final metastable conformation render AAT with intrinsic misfolding and polymerization propensity—e.g., disorder. The Z-mutation (Glu342Lys) exacerbates this folding challenge seen for the wild-type (WT) AAT in the ER. Substitution of Glu342 by Lys slows down the folding rate of AAT [65] and deregulates the opening of β -sheet A, which leads to a misfolded intermediate (*M**) and an increasing tendency to form polymer (*P*) through a “loop-sheet” mechanism [40, 57, 58, 62, 66–68] (Fig. 4.2c). Additional models for AAT polymerization have also been proposed based on the crystal structures of a dimer of a serpin antithrombin [69] and a trimer of a disulfide mutant of AAT [70], suggesting that folding trajectories of AAT/Z-AAT could be diverse and likely dynamic, all subject to the local PN.

The PN has evolved specialized strategies for each energetic state of a folding species in order to maximize function. Abundant chaperones such as Grp78/BiP and Grp94/Hsp90 orthologs, calnexin, and folding enzymes [peptidylprolyl isomerase (FKBP) and protein disulfide isomerase (PDI) family members] in the ER, among

Fig. 4.2 The APL in the AATD context. **(a)** Newly synthesized AAT polypeptide (*U*) has high free energy and large entropy, which folds into native state (*N*) through intermediate state (*I*) in the ER and secretes into serum. Shown is the structure of the native conformation (1QLP) of AAT with reactive center loop (RCL) in red and β -sheet A in blue. **(b)** Abundant circulating AAT and locally secreted AAT inhibits NE to protect the integrity of lung tissue. **(c)** In ZZ-homozygous variants (or WT AAT in response to environmental stress), the folding of AAT may be trapped in a misfolded intermediate (*M*^{*}), which leads to accumulation of a polymer (*P*) in the ER. Here, the PN functions as a “cloud” surrounding each proteins folding state (the APL client) to help them traverse the free-energy barriers and/or sort different folding species to different destinies (i.e., lead the native folded monomeric state to the export pathway, a transiently misfolded intermediate to ERAD, and the polymer for degradation by the ER-phagy pathway). **(d)** Only 10–15 % Z-AAT is secreted into serum in AATD, which leads to continuous degradation of connective tissue by uninhibited NE, protease 3 (PR3), cathepsins, and metalloproteinases (MMPs). NE also stimulates the release of proteases (cathepsins and MMP-2) and chemotactic mediators (leukotriene B4 (LTB4) and IL-8) to accelerate lung damage. Digested elastin fragments and extracellular polymerization of Z-AAT contribute to lung disease through their chemotactic effect for monocytes and neutrophils, respectively. The trans-tissue inflammatory factors delivered from lung to liver exacerbate the folding challenge in the liver. We suggest that proteostasis regulators that modify the activity of the APL, chemical or pharmacologic chaperones that stabilize Z-AAT, HATs/HDACs regulators that adjust the Q-state and APL for a more productive folding event, as well as antioxidants and anti-inflammatory drugs, may provide therapeutic interventions to leverage the diseased APL back to a healthy APL and hence correct AATD

many others, prevent the aggregation of newly synthesized WT AAT polypeptides and help them reach a conformation that can be efficiently exported by the coatomer protein complex II (COPII) vesicle budding system [26, 71–79] (Fig. 4.2a). In contrast, because the folding of Z-AAT is extremely slow and thermodynamically compromised compared to WT AAT [65], the folding intermediates can be trapped

by the chaperones found in the ER [72, 80], a state which contributes to the increased concentration of intermediates susceptible to aggregation/polymerization—with only a small pool of Z-AAT apparently available secretion in its metastable state yielding a reduced serum load of 10–15 % that of WT.

We now appreciate that the ER PN has a set point that detects and partially targets the prolonged Z-variant intermediate for degradation through N-linked glycosylation pathways during its folding [75]. Here, polypeptides that cannot achieve sufficient thermodynamic stability in a biologically relevant time frame are processed by ER mannosidase (ERManI), removing several additional mannose units that typically occur in WT AAT processing for export. The energetics contributed by this processing event remains to be established. These intermediates are retro-translocated to the cytosol for degradation by the proteasome through the glycan ER-associated degradation (G/ERAD) pathway [81–89]. In contrast, Z-AAT polymers/aggregates, which have been suggested in the past to be chaperone free (a point that requires further evaluation), cannot be degraded by G/ERAD pathway. One possibility is that the energy barrier for unfolding and/or retro-translocation across the ER membrane is too high. However, the PN has an alternative pathway to clear them by activating an ER-associated autophagy response (ER-phagy) [42, 43, 88, 90–96]. Therefore, these diverse folding species of Z-AAT with different biochemical/biophysical properties defining their Q-states are differentially recognized by the PN. This differential recognition defines their cellular fates and patient phenotype (Fig. 4.2c).

Remarkably, the ER APL is capable of resolving most proteostasis challenges in the liver brought on by the Z-mutation early in life, illustrating its robustness, since only about 8 % of ZZ-AAT homozygous newborns develop clinically significant liver disease [40, 42, 47, 97]. However, what changes during aging are the cumulative environmental and/or inherited/sporadic challenges leading to enhanced folding stress impacting APL function. This includes both genetic modifiers and environmental factors that either increase the Z-AAT folding challenge or decrease the proteostasis capacity [5] as well as the activity of the decaying stressed PN environment in response to disease [19, 30]. This contributes to late-stage liver and lung dysfunction characteristic of the aging AATD patient. Studies comparing the fibroblasts from “susceptible” and “protected” ZZ individuals reveal that a lag in degradation of translocated Z-AAT correlates with liver disease phenotype [40, 42, 82, 97], and a single nucleotide polymorphism that suppresses the translation of a key ERAD player, ERManI, was found to accelerate the onset of end-stage liver disease [98]. Thus, an increasingly impaired proteostasis program alters the APL and contributes to an early onset and/or a more severe form of the disease. It remains possible that the converse is also true—ZZ-AAT individuals with a more resilient PN may actually be protected and not be detected in the clinic until a very late stage of disease in response to either modifiers and/or management of the environment. It now becomes imperative to identify the role of the PN from the perspective of potential therapeutic targets reflecting the personalized proteostasis biology of the patient (see below).

AATD, Proteostasis, and Lung Disease

Unlike liver disease which can be detected in infants, the lung usually develops the first signs of AATD in early to late adulthood, suggesting that the increasing burden of misfolded/polymerogenic Z-AAT derived from the liver and delivered via plasma to the lung generates an increasingly severe chronic PN challenge leading to pulmonary disease. Environmental pollutants (e.g., cigarette smoke) and pathogens (e.g., bacteria and viruses) that continually challenge the proteostasis program in the airway either directly through protein damage (e.g., oxidative modification) or indirectly through immune/inflammatory responses create additional stress that exacerbates onset of disease in the absence of protection by AAT [31]. For example, the risk of AATD lung disease is markedly increased by cigarette smoking, which can inactivate AAT (and other proteins [99]) through oxidation of the methionine residues in the RCL of AAT [99–103]. Moreover, cigarette smoking exacerbates the polymerization of both extracellular [104] and intracellular Z-AAT [105], decreases the transcytosis of circulating AAT from the capillary to alveoli [106], and upregulates the pro-inflammatory phenotype of lung cells that challenges the PN [105, 107]. Thus, cigarette smoking changes the structural/functional activity of AAT from multiple perspectives along the lung–plasma–lung axis to damage the proteostasis system of the lung independent of its impact on liver physiology, although increasing evidence suggests that cigarette smoke can contribute to liver disease.

The most prominent effect of the absence of AAT function in the lung is markedly increased NE activity leading to breakdown of the alveolar space. Specifically, inflammation in the alveolar wall induces the migration of neutrophils from alveolar capillary into the interstitium between the capillary endothelium and alveolar epithelium (Fig. 4.2b) [40, 42, 97, 108]. NE as well as protease 3 [109, 110], matrix metalloproteinases [111], and cysteinyl cathepsins [112] released from neutrophils degrade the lung interstitial matrix containing fibrillar collagens, elastic fibers, and proteoglycans and cause lung damage that leads to emphysema/COPD [23, 27, 113]. Although normally abundant circulating AAT enters the alveoli by transcytosis from circulating plasma [106, 114] to inhibit these proteases, local cells such as neutrophils [115], macrophages [116], and type II alveolar cells [117, 118] also produce AAT to protect the lung [40, 42, 97]. Thus, AAT functions as a component of a poorly understood PN network outside of the cell [17] to protect the integrity of the extracellular exposed lung proteome in response to inflammatory stress (Fig. 4.2b). However, in ZZ homozygotes, because the level of AAT in serum is only 10–15 % of normal healthy pool, this leaves the lung tissue subject to degradation by NE (Fig. 4.2d). Furthermore, because NE can stimulate the release of cathepsin B and matrix metalloprotease-2 from macrophages [119], this can exacerbate lung damage as the resulting degradation products are found to have a chemotactic effect for monocytes [120]. NE also upregulates the release of chemotactic mediators such as leukotriene B4 [121] and IL-8 [122], which leads to an increased concentration of neutrophils in the bronchoalveolar lavage (BAL) of AATD patients [40, 42, 97, 123]. Thus, the extracellular protease–antiprotease imbalance triggers a cascade of proteostasis mis-managed destruction of alveolar wall that causes defective alveoli (Fig. 4.2d).

Besides the loss-of-function mechanism, intracellular Z-AAT polymerization inside the monocytes [40, 67, 124] and/or lung epithelial cells [105] was shown to induce ER stress and release of inflammatory factors. Moreover, Z-AAT aggregates have been found in the BAL [125] and serum [53] of AATD patients. Given that polymer can be detected in patients that have undergone liver transplantation [126], these results potentially implicate a role of Z-AAT secreted from lung cells in polymer formation and accumulation in the lung. Some evidence suggests that extracellular polymerization of Z-AAT in the lung causes the influx of neutrophils into alveoli [126, 127] and further contributes to lung pathophysiology (Fig. 4.2d). Therefore, the misfolding/aggregation of Z-AAT is not restricted to its cell-autonomous impact on liver pathophysiology, but could play a prominent role in both cell-autonomous and cell-nonautonomous roles in the lung, confounding our understanding of the underlying proteostasis events responsible for the temporal (aging) and spatial (liver–plasma–lung axis) mitigation of disease.

Rationale for Managing the APL

The proteostasis problem is central for both liver and lung disease in AATD, so understanding the role of the PN is crucial for formulating new approaches for AATD disease intervention. The PN is a multilayered and fully integrated system composed of components that generate, maintain, regulate, and remove proteins [18, 20, 23, 26, 28, 30, 37]. As described in detail by Powers and colleagues [20], we define the innermost layer of the PN as the components that directly interact with and/or that affect the target protein including protein synthesis systems (transcription/translation machineries), folding/unfolding systems [chaperones and folding enzymes (the chaperome)], posttranslational modification systems (glycosylation, phosphorylation, acetylation and oxidation, among many others), trafficking systems (the exocytic, endocytic, and lysosomal pathways), and degradation systems including the ubiquitin–proteasome system (UPS) and the autophagy–lysosome axis managing the fate of cellular aggregates. The second layer of the PN is composed of multiple signaling pathways including the heat shock response (HSR), the unfolded protein response (UPR), and oxidative stress and inflammatory responses that modulate the composition, concentration, and function of the PN components comprising the innermost layer. These signaling pathways can trigger a cascade of events that promote cell/tissue health, reprogram the cell/tissue for repair or destruction, and/or support a malignant phenotype as found in neonatal liver disease [32, 128, 129]. The third, outermost layer includes environmental/physiological stressors, metabolites, and genetic/epigenetic factors that modify the first and second layer and are driven by the extracellular environment. Biology utilizes this sophisticated network to generally maintain the healthy state of the proteome that is susceptible to continuous genetic and environmental challenges, but is clearly challenged by the Z-variant and, for example, overwhelmed by a combined Z-mutation folding stress and an oxidative cigarette smoking-derived proteostasis

stress in AATD. To deal with the folding trajectory, it is now thought that the PN may recognize proteins based on their variable energetic standards contributing to a set point [19, 29, 30] that is sensitive to the unique proteostatic composition in each cell type and that is highly adaptable to the constantly changing stress that proteome misfolding places on proteostasis buffering (reserve) capacity. Moreover, recent studies show that proteostasis composition is under direct neuronal and neuroendocrine control [33, 130–132], leading to the recent suggestion that proteostasis cross talk between tissues, such as the liver–plasma–lung axis, could be integrated through the central and peripheral nervous system.

The above insights indicate that the conventional view that a single native protein conformation is “the” functional state is incorrect. It is likely that most proteins, particularly metastable AAT and its further destabilized Z-AAT variant, populate multiple intermediate functional states transiently associated with PN components throughout their lifetime, referred to as the “cloud” responsible for protein stability and evolvability [19, 35, 133]. Thus, it is the PN cloud that gives function to the dynamic Q-state of the protein fold in biology. In the case of WT AAT, while the cloud prepares the monomer to fulfill function as a NE inhibitor outside the cell, the polymer functions (in the context of the PN cloud) as a pro-inflammatory component that the tissue uses as a metric to call for support through immune responses. Besides the Z-mutation which dominates the current focus, there are over 100 different ATT mutations—more than 30 of which are found to affect either the level or function of AAT [134]. Interestingly, the thermodynamics of folding intermediates of most mutants (including Z-variant) are not dramatically different from that of WT AAT, but rather populate a series of modest free-energy wells in the folding energy landscape [135–137]. Where WT protein can easily traverse these energy wells with the help of the PN, AAT variants may become trapped and concentrated by local proteostasis cloud components because of either kinetic or thermodynamic problems contributed by the mutated Q-state structure (Fig. 4.2c). The fact that the diverse PNs in different cell types and compartments provide different levels of proteostatic capacity that are differentially sensitive to PN signaling pathways implies that the APL could be sculptable through reprogramming the PN [18, 20].

Z-AAT as a Sculptable Proteostatic Stress Modulator

Here, we use the folding of Z-AAT in the ER as an example to describe how the PN could modulate the APL and hence the disease phenotype. This description provides clues as to how we might leverage proteostasis to promote correction if we understand the mechanism(s) of action behind the interplay between the mutant protein fold and the local proteostasis cloud facilitating the folding trajectory.

While the tentative folding landscape of Z-AAT is shown in Fig. 4.2c, it is undoubtedly much more complicated. Each of the folding species dominating Z-AAT biology [e.g., *U* (unfolded nascent chain), *I* (on-pathway folding intermediate), *M** (off-pathway folding intermediate), *N* (native conformation), and *P* (polymer)]

is maintained by pathways that include PN-assisted ER translocation, ER folding and glycosylation [simplified as ER-associated folding (ERAF)] [19, 20, 138], degradation (ERAD, ER-phagy) [93], and ER export (COPII) [19, 138–141]. AAT is an acute-phase protein with its expression level increasing three- to fourfold in response to inflammation; thus, the ER import of U is highly variable and dependent on the signaling pathways dictating the functional needs of the cell, tissue. When the amount of U exceeds the capacity of ERAF that is critical to help stabilize metastable folding intermediates and prevent the aggregation of U , a process challenged by the thermodynamic/kinetic instability of all AAT mutants, the folding equilibrium of AAT, and particularly Z-AAT, will inevitably flow through the M^* and P pathways. Indeed, indomethacin, which activates IL-6-STAT3 cytokine signaling pathway and increases the expression level of Z-AAT, results in higher levels of Z-AAT polymers and increases liver damage in PiZZ mouse model [142]. Since Z-AAT has slow folding kinetics and low thermostability compared to WT AAT, the interconversion between I , M^* , and N , being concentration dependent, favors the conversion from M^* to P (or to a lesser extent from N to P). This process is unidirectional because once the polymer is formed, the stable conformation has an apparent large energy barrier for unfolding that the polymer cannot bypass [143, 144]. A solution that nature has evolved to remove such misfolded aggregates is to subcompartmentalize these thermodynamically stabilized structures in specialized, sealed degradation autophagic compartments [29, 43, 88, 90, 91]. This illustrates that by changing the APL through redefining the composition of the PN, the cell can flip the problem on its head to aggressively protect against aberrantly misfolded species.

The need for increased degradative capacitance to protect the cell from aggregated species is consistent with the observation that inhibiting ERAD without changing the capacity of ERAF and ER export increases the polymer level and contributes to AATD liver disease phenotype [82], reinforcing the interpretation that the dynamic folding equilibrium is under continuous control by the PN. Since our ultimate goal is to correct both liver and lung disease in AATD, we suggest that augmentation of ERAF and/or ER export machineries could increase the I - N folding pathway and decrease M^* - P folding pathway, thus making the folding landscape of Z-AAT more like WT AAT as shown in Fig. 4.2a, possibly acutely or permanently correcting the fold by subtle changes in the APL [91, 145–147].

Proactive Proteostatic Signaling Pathways Activated by Z-AAT

The goal of proteostasis therapeutics is to use biology to fix biology by targeting the support pathways whose roots are 3.5 billion years old [19]. Remarkably, it is clear that biology, in response to the environment, has evolved many ways in phylogenetic diverse cell types to manage the fold and folding stress using common principles [19]. The versatility of the folding program should, in principle, be able to address challenges such as occurs in AATD-inherited disease through

reprogramming [18]. While HSR [3] is the universal response found to manage folding in all phyla, in eukaryotes the UPR [4] has evolved to handle misfolded proteins traversing endomembrane compartments. As such, each compartment relies on multiple but often unknown inputs to elicit highly variable and dynamic responses to handle folding challenges that either address the problem or found to be insurmountable and drive the cell down death pathways. Interestingly, Z-AAT does not activate the classic ER UPR signaling pathways that involve the IRE1, PERK, or ATF6 cytosolic transcription factors in hepatocytes [148–150]. The inability to generate an UPR response and promote complete degradation of misfolded Z-AAT through G/ERAD in hepatocytes could reflect the fact that the monomer and the polymer are actually considered as Q-state “normal” by the ER UPR signaling sensors, perhaps as a native but metastable “folded” structure that contributes to the dynamic “mouse-trap” mechanism [151]. However, the increased propensity to disorder in variants such as Z leads to a Q-state that largely defines a polymeric autophagic substrate and a modest substrate for G/ERAD.

In contrast to hepatocytes, Z-AAT induces UPR in monocytes where its expression is low [124]. Thus, in different proteostasis environments in which the aggregation phenotype may be reduced because of a smaller load of Z-AAT nascent chain whose polymer propensity is logarithmically proportional to concentration like amyloid, Z-AAT folding species may be sufficiently long-lived to be preferentially targeted to G/ERAD pathways [92]. These differences emphasize that diverse proteostatic dynamics found in different cell types can be targeted specifically by unique modifier therapeutics. Moreover, we have recently reported that the sustained expression of Z-AAT induces a maladaptive stress response (MSR) through chronic activation of the HSR pathway found in the cytosol [30]. A similar observation was reported in yeast where overexpression of a misfolded luminal protein CPY* was found to activate HSR [152]. Activation is unlikely due to UPR and/or altered G/ERAD because this phenomenon is observed in Ire1Δ strain in which both UPR and ERAD are impaired [152]. Importantly, we have shown that silencing HSF1, the HSR master regulator, either chemically or through the use of biologics (siRNA) restores the secretion of functional Z-AAT, indicating that the MSR confounds the disease phenotype in its attempt to solve it but cannot fix due to the chronic nature of the disease [30].

An additional proteostatic impact that has been noted in AATD is that the accumulation of Z-AAT activates oxidative stress [153] and inflammatory NF-κB pathways [27, 40, 148, 150] (or ER overload response [154]). How NF-κB pathway affects the PN is not well understood [27], but the inflammatory factors upregulated by this pathway, as well as trans-tissue inflammatory signals delivered from lung to liver (Fig. 4.2c, d), could increase the expression level Z-AAT, which may improve secretion but also could result in a higher production of polymer.

The above examples illustrate that proteostatic control in AATD could emanate from multiple and diverse signaling pathways reflecting the local cell and tissue PN response. A detailed understanding of the “personalized” folding of Z-AAT managed by proteostasis in these different cell, tissue, and host environments could

provide critical insights into unappreciated nodes in a correction network within the global PN impacting human disease.

Current Therapeutic Opportunities

AAT augmentation (replacement) therapy is the only specific noninvasive treatment for AATD [135, 155–159]. Replacement therapy is based on the concept that the patient should be able to restore the basal level of AAT by weekly intravenous purified human AAT, an approach that may slow or stop the progression of lung disease [135, 155–157, 160]. This treatment is indeed capable of contributing to the serum AAT pool above the protective threshold and to increase the anti-NE activity in BAL [155, 158, 161, 162]. However, the clinical impact of this treatment for lung function remains controversial [135, 156–159, 163–165]. The lack of a clear validated clinical impact by augmentation therapy could reflect the absence of well-controlled clinical trials to statistically assess apparent impact. Alternatively, the mechanism(s) responsible for lung disease could be much more complicated than just a shortage of circulating AAT below the protective threshold, perhaps reflecting the impact of the Z-AAT being produced by all cells (liver and lung), creating a proteostatic stress along the liver–plasma–lung axis by disrupting general proteostasis capacity and/or inhibiting the secretion of other unknown proteins/factors required for health. For example, issues such as acute-phase response and gain of toxicity of Z-AAT aggregates in the liver cannot be addressed by augmentation therapy. Moreover, the lung Z-AAT likely continues to create a burden that triggers inflammatory responses detrimental to lung health [134]. Furthermore, the continued production of Z-AAT could be a competitive inhibitor of perfused WT AAT function through as yet to be defined extracellular and transcellular proteostasis pathways [17, 19]. Environmental or genetic factors may also contribute to the efficacy of augmentation therapy from a personalized perspective that can only be resolved by understanding the steady-state dynamics of the APL in the liver, plasma, and lung and the impact of modifiers among the patient population.

In addition to augmentation therapy [135, 155–159], the liver and lung transplantation provide highly invasive but optional strategies for both early- and late-stage AAT-associated liver and lung disease [41, 166]. These treatments come with high risk and do not solve the global APL challenge from the perspective of continued Z-AAT production by other tissues. Progress on new therapeutic investigations reviewed elsewhere also comes from the perspective of gene therapy [167, 168], polymer inhibitors [40, 44, 53, 67, 68, 149, 169–172], and autophagy regulators [42, 43, 96, 146, 173, 174]. Below we will describe new opportunities for AATD drug discovery through proteostatic modulation of the APL.

Therapeutic Management Through the AATD Stress Chaperome

Chaperones (e.g., chaperonins, Hsp70, Hsp90 comprising the chaperome family) were initially described as proteins that assist non-covalent folding and assembly of polypeptides [2, 4, 14, 175, 176]. However, it is now recognized that chaperones also assist unfolding [177, 178], degradation [18, 21, 179–183], and trafficking [26] and direct the regulation of the biological function of thousands of client proteins including kinases driving cancer [128, 183, 184], DNA and RNA polymerase components [185, 186], transcription factors [187, 188], longevity factors [6, 189–191], most cell surface signaling receptors responsible for signaling proliferation (e.g., EGFR and steroid hormone receptors) responsible for metastatic disease [192], and cytoskeletal function [193, 194]. Chaperones also transmit the signal for misfolded proteins to activate UPR and HSR to manipulate the proteostasis capacity of the cell [4, 6, 18, 129]. Thus, chaperones provide the biological framework for regulation of the protein fold for function. They are potential key drug targets to manipulate both the dynamic Z-AAT folding Q-state and the signaling pathways controlling the PN that could alter folding dynamics to a more functional state to stabilize disease.

The major chaperones that bind Z-AAT in the ER include calnexin-UGGT system and GRP78/BiP (orthologue of the cytoplasmic Hsp70 family members) [4, 72, 80]. Through BiP, the secretory pathway is usually considered as a quality control system that only secretes the native conformer [22, 195, 196]. However, the concept of quality control is a misnomer. Rather than the native conformation per se, it is the global protein energetics and the variable PN that determine the success or failure of folding, export, and function and that is sensitive to genetic and epigenetic programs that define the physiology of each cell type [3, 30, 131, 139, 197, 198]. For Z-AAT, which is intrinsically metastable, competition for export and degradation components along the exocytic pathway will ultimately determine the final yield in the serum, emphasizing that it is not the AAT protein per se but the Q-state proteostatic cloud dominating trafficking pathways that dictates function driving liver and, ultimately, lung biology. While the ER export trafficking component ERGIC-53 has been suggested as a cargo receptor for WT AAT directing ER to Golgi exit, its interaction with Z-AAT is extremely low in the cell [44, 74, 199]. Multiple reasons could contribute to the low cargo receptor binding affinity for Z- compared to WT AAT including the following: (1) a large portion of Z-AAT is masked by the BiP/calnexin cycle; therefore, little Z-AAT is released for ERGIC-53 binding; (2) ERGIC-53 does not recognize the nonnative conformation of Z-AAT based on its thermodynamic or kinetic folding properties; and (3) the Z-AAT monomer–polymer balance in the ER is dominated by polymerization given its high concentration in the hepatocyte, an altered state that is not recognized efficiently by ERGIC-53. Thus, additional experiments are required to understand the underlying mechanism for ER export beyond the simple concept of quality control.

Other stress chaperones reported to interact with Z-AAT include GRP94 (orthologue of cytosolic Hsp90) [72, 200], GRP170 [72] and PDI [73], as well as numerous BiP and GRP94 co-chaperones—all poorly studied [40, 41, 201]. Collectively,

we refer to folding mediators as the ER “chaperome” that determines both the functional and degradative trajectory of the fold. Mutations in BiP lead to temporal impairment of ERAD of Z-AAT [179], and silencing of calnexin through siRNA increases the secretion of Z-AAT [202], which implies that these chaperones can alter the folding of Z-AAT in the context of their expression levels and the PN chaperome dynamics of a given cell type. This provides a simple demonstration that primary sequence, while important, provides a code that can be (re)interpreted by the chaperome/proteostasis system reflecting context.

The general mechanism used by chaperome biology is the dynamic binding and release of nonnative folding species to promote acquisition of the final folded state, presumably by preventing the formation of nonproductive, irreversible folding intermediate states (Figs. 4.1 and 4.2). Thus, it is not surprising that chaperones delay Z-AAT export from the ER since Z-AAT folds slowly and tends to misfold and therefore may reside more frequently in a “chaperone trap” by analogy to misfolded F508del CFTR [203]. However, the recognition that a substantial fraction of the Z-variant can escape the ER to yield a 10–15 % steady-state population in the plasma suggests that at a less populated state compared to WT AAT, Z-AAT occupies an energetically comparable folded state acceptable to the ER export machinery. Chaperones are also likely to be critical to manage the aggregation state of Z-AAT in the ER. However, no studies to date have addressed therapeutic management of Z-AAT through direct ER chaperome intervention.

What, then, could be the sequential events amenable to chaperome therapeutic intervention? We appreciate that the Z-AAT nascent chain enters the calnexin-UGGT cycle after co-translational removal of two glucose units by glucosidases I and II and then associates with BiP and ER export machinery components [75, 85]. ERAD is initiated when the binding of BiP reaches a peak. Thus, it seems that while the calnexin cycle is important for the initial folding and glycosylation of Z-AAT, BiP associates with Z-AAT in a late stage of folding and plays a central role in determining the balance of export, degradation, and aggregation. BiP alone is unlikely to be a direct drug target given its essential role for the folding of nearly all client proteins entering and/or exiting the ER and its critical role in controlling the UPR signaling pathway [4]. However, the function of BiP is regulated and diversified by its co-chaperone DNAJ proteins and nucleotide exchange factors (NEF) [72, 97, 204]. DNAJ proteins, which assist in client (AAT) delivery to BiP, often have distinct and specific client protein-binding properties due to their diverse structural organization in addition to the presence of the conserved J domain that interacts with BiP to promote function. After client protein binding, DNAJs recruit BiP, deliver the client protein, and stimulate BiP’s ATPase activity to stabilize the client-BiP protein bound state. The release of the client protein from BiP is facilitated by NEFs (also called BAGs), which catalyze the exchange of ADP to ATP. There are seven DNAJ proteins and two NEFs that have been identified in the ER [205, 206]. However, there are few insights into their potential roles in WT and Z-AAT maturation. One NEF protein, GRP170, has been reported to interact with Z-AAT [72, 207, 208]. It would be interesting to see whether these co-chaperones play roles in determining the fate of Z-AAT delivery either to ERAD, aggregation, or export, since

targeting the binding interface between BiP and its co-chaperone and/or directly targeting co-chaperones is emerging as a new therapeutic opportunity. For example, targeting the cytosolic Hsp40-70 chaperome system for treatment of neurodegenerative disease and cancer is an active area of therapeutic development [2, 129, 181–183, 209, 210]. Consistent with this approach, we have suggested that elimination of chronic HSR (MSR) could restore the secretion of Z-AAT through MSR management [30]. These results point to the unanticipated direct or indirect importance of influence of the HSR on ER folding environment governed by the UPR and the cytosolic chaperome for modulating the APL of the Z-AAT. Though cytosolic chaperones are not directly involved in the folding of Z-AAT inside the ER, they have been shown to be critical for ERAD [211], autophagy [42, 91, 95, 96, 146, 212], and membrane trafficking [213]. Thus, it will be interesting to investigate how this proteostasis environment influences the general operation of the ER and downstream trafficking compartments in the management of Z-AAT proteotoxic stress in the liver and its function in the lung and whether they can be manipulated therapeutically through proteostasis regulators.

Therapeutic Management Through an Emergent Membrane Trafficking Proteostatic Code Driving Eukaryotic Biology

Numerous highly evolved endomembrane systems direct eukaryotic function [19, 26]. These provide optimal fold management systems reflecting the unique cellular, tissue, and organismal environmental challenges defining the APL. As such, trafficking has been proposed to be an extension of the proteostasis network [19, 26] with the trafficking machinery itself (the SNAREs, tethers, and vesicle-forming coats) defining the compartmentalized structure of folding pathways that facilitate delivery of protein to post-ER intracellular compartments [19, 26] and the extracellular space [17]. In the case of Z-AAT, folding species are exported out of the ER by COPII-coated vesicles [78, 214–218], which can mediate anterograde transport toward the Golgi and/or contribute to autophagosome formation [4, 42, 93, 94], divergent compartmentalization events impacting protein function [215, 219–221]. Exported material may be recycled back from Golgi compartments to the ER by the COPI coat system [78, 222, 223], refining the function of the ER folding environment and optimizing the composition of downstream Golgi and endocytic compartments [224]. The versatility of endomembrane trafficking design is consistent with the observation that Z-AAT can even exit the ER as a membrane-surrounded inclusion body, which is negative for autophagosomal and lysosomal markers, and can be inhibited by overexpression of calnexin [225]. Moreover, the ER has also been suggested to have COPII-independent mechanisms to dislocate large protein complexes involving the ER degradation-enhancing α -mannosidase-like protein 1 (EDEMI) [226, 227], though the mechanisms remain unknown. Therefore, we consider membrane trafficking programs as dynamic modulators of the Anfinsen physiological state [26, 228], which utilizes developmentally specialized compartmentalization of

PN components to optimize use of the APL in each cell type, providing unique folding environments to respond to diverse proteostasis management signaling pathways that promote cell, tissue, and organismal survival.

Given the above, an untapped question is: how does the ER trafficking machinery recognize different energetic states of the incredibly diverse folding species exiting the ER to assess their specific destinations, such as autophagy, inclusion body, and/or ER-to-Golgi trafficking by COPII-dependent and/or COPII-independent mechanisms? Conventional ER export vesicles are coated by COPII complex, which have a typical size around 60–70 nm in diameter. Remarkably, we now appreciate that the size can be optimized depending on particular cargos, for example, collagen fibers (~300 nm) and lipoprotein particles (150–500 nm) require 300 nm vesicles [26, 215, 229–231] through the chaperome machinery. Cargo selection for export is initiated through the Sec23/24 adaptor complex that is subject to multiple posttranslational modifications for function [218, 232]. However, recent evidence suggests that the ability to generate diverse vesicle sizes that allow it to recruit large cargo involves additional trafficking components such as the adaptor escort proteins TANGO1 [233] and cTAGE5 [234] linked to the ER membrane. Moreover, it is sensitive to the ubiquitination state of one of the COPII components, Sec31 [26, 77, 229]. It will be interesting to see whether the size of COPII vesicles can be manipulated to differentially recruit WT and Z-AAT monomer or polymers for export as a therapeutic strategy. Even when Z-AAT successfully reaches in Golgi, resident proteins such as VIP36 and the KDEL receptor have been suggested to retrieve it back to the ER by interaction with its associated BiP [235]. VPS10 at the trans-Golgi has been shown to direct Z-AAT to lysosome for degradation [236], although it remains possible it has a normal function as an antiprotease inhibitor in the lysosome. Whereas considerable insight has been gained in understanding co-translational insertion and folding of the nascent chain in the ER, much less is known about the operation of the downstream trafficking compartments that could augment the protein fold through the COPI-mediated refinement and additional posttranslational modifications [78, 222, 223] that, when defective, are responsible for numerous pathological syndromes [26, 237]. Therefore, the unstable Z-AAT meets many challenges that can hinder its progress through exocytic pathway, highlighting the role of membrane compartments as proteostatic managers of the Q-state by generating sequential APLs. Additional studies may contribute to understanding the limitations restricting Z-AAT trafficking to serum for function in the lung.

Therapeutic Intervention Through the Acetylation–Deacetylation Network (HATs and HDACs)

We now appreciate that modifications of surface lysine (Lys) residues through competitive pathways of acetylation and ubiquitination can have a major impact on the Q-state responsible for protein stability and function by altering the response to the APL [19, 28–31]. The role of ubiquitination of surface Lys residues is complex and has been extensively reviewed [238]. Here, we focus on the impact of histone

acetyltransferase (HAT) and histone deacetylase (HDAC) in managing the APL in AATD.

HATs and HDACs mediate acetylation and deacetylation, respectively, modifications on the Lys residues of histones and nonhistone proteins. The acetylation status of a protein has a major impact on proteostasis pathways. While these modifications are well known to have an important role in the context of “epigenetics” that (re) program gene expression through histone modifications controlling nucleosome structure, we view a more general function of HATs and HDACs as “proteostatics” that modulate the charge status of surface Lys residues and, therefore, modify the Q-state for novel function in response to the local APL (Fig. 4.3). The importance of HAT/HDAC proteostatic activity is particularly evident not only in their impact in modulating posttranslationally the activity of many APL client proteins comprising the acetylome, but almost all PN components, including the core chaperones (Hsp90 [239], Hsp70 [240], Hsp40 [241], BiP [242, 243]), the HSR transcription factor HSF1 [244], degradation processes (by directly competing for Lys ubiquitination [245]), and membrane trafficking components including the assembly of microtubule and actin cytoskeletal polymers responsible for positioning and directing traffic through both the exocytic and endocytic pathways [246, 247]. Thus, HDACs globally impact proteostasis pathways by subtly modulating the thermodynamics and kinetics of the Q-state cloud biology in the context of the HDAC-

Fig. 4.3 The role of proteostatics in survival and fitness. Shown is the relationship between survival and fitness that is imprinted in genome through genetics, and epigenetic and proteostatic programs that are responsive to the environment. Genetics are defined by the inherited genome in the population that contributes to survival and fitness. Epigenetics, through histone modification of Lys residues by HATs/HDACs, alters the transcriptional environment of chromatin contributing to gene expression that promotes survival and “epi” (non-)genetic fitness in the population. We now appreciate that proteostatics encompasses not only the PN but includes epigenetics defined by HAT/HDAC-mediated acetylation–deacetylation pathways and contributes to the dynamic Q-state of the fold to promote daily survival in response to the environment and long-term fitness through modification of the genome

sensitive APL. In this view, proteostatic pathways that clearly encompass HDACs are potentially a therapeutic responsive real-time manager of protein folding imbalance in the cell [248] (Fig. 4.3).

Given the above, it is therefore not surprising that HDAC inhibitors (HDACi) have been shown to have beneficial effects for many protein misfolding diseases, such as cystic fibrosis [249], Gauchers disease [250], muscle atrophy [251], Niemann–Pick C [252, 253], and neurodegenerative diseases [254–258]. Specifically, we have shown that the pan Class I/II/IV HDACi suberoylanilide hydroxamic acid (SAHA) restores the secretion and activity of Z-AAT to ~50 % of the level that observed in WT AAT [27]. Currently, this correction appears to be mainly through inhibition of HDAC7, which is the same HDAC target that can be modified by SAHA to correct the folding of the most common mutation found in cystic fibrosis, F508del [249]. Incubation with SAHA or silencing of HDAC7 improves AATD through multiple pathways. For example, we have found that it upregulates the synthesis of Z-AAT, helps Z-AAT more efficiently exit calnexin chaperone cycle, modulates the ER redox environment by downregulating the expression of Ero1L, improves ER exit via COPII, and transits through the Golgi for improved secretion at the cell surface, as well as other pathways that we may not appreciate. This may simply be due to the fact that SAHA or silencing of HDAC7 produces a robust proteostatic encoded folding and trafficking environment (APL) for Z-AAT, which, interestingly, persists even after compound withdrawal following a chronic treatment regimen suggesting that imprinting occurs during epigenetic modification by HDACi [202]. Though SAHA-treated cells still produce polymeric Z-AAT, combining SAHA and polymer inhibitors [40, 169–171, 199, 259] may give an increasing yield of monomeric Z-AAT in plasma for lung protection.

In addition to its effect on Z-AAT folding and trafficking, SAHA exhibits anti-inflammatory properties (e.g., [260–264]), which could provide an unanticipated benefit in AATD by modulating inflammation in COPD [27]. However, the role of HDACs in lung biology is complicated. Class I and II HDAC activity is reduced in the lung of COPD patients even though the HAT activity remains unchanged [265, 266]. Moreover, reduction of HDAC2 causes corticosteroid resistance in COPD patients [267] leading to defective regeneration of airway epithelium [221], and reduction of HDAC3 increases the cytokine expression which would enhance inflammatory responses [268]. Besides the members of Class I and II, Zn²⁺-dependent HDACs targeted by SAHA, SIRT1, one of the class III NAD(+) -dependent HDACs, is also reduced in lung of COPD patient [269]. Reduction of SIRT1 causes increased acetylation of histone H3 and NF- κ B leading to upregulation metalloproteinase-9 expression affecting alveolar structure [270, 271]. In contrast, SIRT1 has been found to protect against emphysema by deacetylation of the FOXO3 transcription factor [272]. Consistent with these results, the SIRT1 activator resveratrol [262] and SRT1720 [273] were shown to alleviate lung inflammation.

In summary, by modulating the acetylation–deacetylation proteostatic balance driven by HAT/HDAC-mediated Lys modification, it may be possible to both recover the shortage of functional antiprotease (AAT) production from the liver and decrease the threat from inflammatory pathways in the lung. However, it is clear that future

studies will be required to understand how the acetylation–deacetylation network managed by the HDAC population in the liver and lung tissue environments contribute to stabilization of function and to develop specific HDAC agonist/antagonists to optimize their impact on rescued Z-AAT in these environments. By using HDACi to alter the Q-state dictating protein folding stability and function, we may be able to synchronize the protein folding and function within the APL of multiple environments, an approach that could have an impact on disease etiology by using the same pathways biology nature has evolved to equilibrate the activity of diverse protein structures in a common proteostatics environment through Lys modification (Fig. 4.3).

Perspective: The Future of Proteostasis Management in AATD

We have described potential rationales and possible strategies to manage the APL and hence the function of the folding proteome responsible for human AATD. Though Anfinsen, who received the Nobel Prize in 1972 [228] for demonstrating that the primary sequence encoded by the genome plays a key role in generating the protein fold, he also posed a major challenge by suggesting that the biologically active conformation of a protein is actually determined by its environment—referred to as the physiological state. For the most part, the current practice of medicine ignores the underpinning dynamics of this physiological state as a focus for therapeutics. Given the evolutionary process [133], by definition we are all mutants. We achieve function as a consequence of proteostatic optimized evolvability [19, 34, 192, 274] that promotes daily survival and ultimately, through emergent proteostatics, fitness [19, 35, 275]. During the AAT functional cycle, the RCL needs to fully insert into the β -sheet A to flip the targeted elastase to another side of AAT [63, 64], which is likely thermodynamically and/or kinetically favored by the Z-variant mutation due to the increased metastability of the β -sheet A. However, this potential “functional” adjustment renders Z-variant polymerization propensity too great since the metastable β -sheet A also induces the intermolecular RCL insertion [40, 199, 276]. Such “off-pathway” mutations persist through evolutionary selection because of the highly evolved PN, which buffers these out-of-balance energetic states [19, 274]. Only when the normally robust PN is impaired in response to global stress or chronic aging does the “misfit” folding species begin to exhibit its proteotoxic function as occurs in AATD. We are now at the beginning of our efforts to remove the cloak masking the role of the PN in managing inherited genetic changes—proteostatic buffered changes that have worked in a positive sense and exceedingly well over the last 3.5 billion years to evolve and diversify extant life [19, 275]. We project that future studies defining proteostatic principles will provide insights and tools to adjust the dysfunctional APL found in AATD back to a healthy state, leading to reduced fragility and improved resilience of the liver and lung environments.

Acknowledgements This work was supported by grants from National Institute of Health GM33301 and GM42336 for WEB, TRDRP 21XT-0070. CW is supported by postdoctoral research fellowship from Alpha-1 Foundation.

References

1. Wolynes PG, Onuchic JN, Thirumalai D. Navigating the folding routes. *Science*. 1995;267(5204):1619–20.
2. Kim YE, et al. Molecular chaperone functions in protein folding and proteostasis. *Annu Rev Biochem*. 2013;82:323–55.
3. Morimoto RI. The heat shock response: systems biology of proteotoxic stress in aging and disease. *Cold Spring Harb Symp Quant Biol*. 2011;76:91–9.
4. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. *Science*. 2011;334(6059):1081–6.
5. Morimoto RI, Cuervo AM. Proteostasis and the aging proteome in health and disease. *J Gerontol A Biol Sci Med Sci*. 2014;69 Suppl 1:S33–8.
6. Vilchez D, Simic MS, Dillin A. Proteostasis and aging of stem cells. *Trends Cell Biol*. 2014;24(3):161–70.
7. Ong DS, Kelly JW. Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases. *Curr Opin Cell Biol*. 2011;23(2):231–8.
8. Tokuriki N, Tawfik DS. Protein dynamism and evolvability. *Science*. 2009;324(5924):203–7.
9. Motlagh HN, et al. The ensemble nature of allostery. *Nature*. 2014;508(7496):331–9.
10. Dunker AK, et al. Intrinsic protein disorder in complete genomes. *Genome Inform Ser Workshop Genome Inform*. 2000;11:161–71.
11. Ferreon AC, et al. Modulation of allostery by protein intrinsic disorder. *Nature*. 2013;498(7454):390–4.
12. Toretzky JA, Wright PE. Assemblages: functional units formed by cellular phase separation. *J Cell Biol*. 2014;206(5):579–88.
13. Uversky VN. A decade and a half of protein intrinsic disorder: biology still waits for physics. *Protein Sci*. 2013;22(6):693–724.
14. Ellis RJ. Macromolecular crowding: an important but neglected aspect of the intracellular environment. *Curr Opin Struct Biol*. 2001;11(1):114–9.
15. Wyatt AR, et al. Extracellular chaperones and proteostasis. *Annu Rev Biochem*. 2013;82:295–322.
16. Evans ML, Chapman MR. Curli biogenesis: order out of disorder. *Biochim Biophys Acta*. 2014;1843(8):1551–8.
17. Powers ET, Balch WE. Protein folding: protection from the outside. *Nature*. 2011;471(7336):42–3.
18. Balch WE, et al. Adapting proteostasis for disease intervention. *Science*. 2008;319(5865):916–9.
19. Powers ET, Balch WE. Diversity in the origins of proteostasis networks – a driver for protein function in evolution. *Nat Rev Mol Cell Biol*. 2013;14(4):237–48.
20. Powers ET, et al. Biological and chemical approaches to diseases of proteostasis deficiency. *Annu Rev Biochem*. 2009;78:959–91.
21. Taylor RC, Dillin A. Aging as an event of proteostasis collapse. *Cold Spring Harb Perspect Biol*. 2011;3(5):1–17.
22. Ryno LM, Wiseman RL, Kelly JW. Targeting unfolded protein response signaling pathways to ameliorate protein misfolding diseases. *Curr Opin Chem Biol*. 2013;17(3):346–52.

23. Bouchecareilh M, Balch WE. Proteostasis: a new therapeutic paradigm for pulmonary disease. *Proc Am Thorac Soc*. 2011;8(2):189–95.
24. Hingorani KS, Gierasch LM. Comparing protein folding in vitro and in vivo: foldability meets the fitness challenge. *Curr Opin Struct Biol*. 2014;24:81–90.
25. Wirth AJ, Gruebele M. Quinary protein structure and the consequences of crowding in living cells: leaving the test-tube behind. *Bioessays*. 2013;35(11):984–93.
26. Hutt DM, Balch WE. Expanding proteostasis by membrane trafficking networks. *Cold Spring Harb Perspect Med*. 2013;3(7):1–21.
27. Bouchecareilh M, Balch WE. Proteostasis, an emerging therapeutic paradigm for managing inflammatory airway stress disease. *Curr Mol Med*. 2012;12(7):815–26.
28. Roth DM, Balch WE. Modeling general proteostasis: proteome balance in health and disease. *Curr Opin Cell Biol*. 2011;23(2):126–34.
29. Roth DM, Balch WE. Q-bodies monitor the quinary state of the protein fold. *Nat Cell Biol*. 2013;15(10):1137–9.
30. Roth DM, et al. Modulation of the maladaptive stress response to manage diseases of protein folding. *PLoS Biol*. 2014;12:e1001998 (ePub Nov 18).
31. Balch WE, et al. Malfolded protein structure and proteostasis in lung diseases. *Am J Respir Crit Care Med*. 2014;189(1):96–103.
32. Walton-Diaz A, et al. Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity. *Future Med Chem*. 2013;5(9):1059–71.
33. van Oosten-Hawle P, Morimoto RI. Organismal proteostasis: role of cell-nonautonomous regulation and transcellular chaperone signaling. *Genes Dev*. 2014;28(14):1533–43.
34. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. *Nat Rev Mol Cell Biol*. 2010;11(7):515–28.
35. Lindquist S. Protein folding sculpting evolutionary change. *Cold Spring Harb Symp Quant Biol*. 2009;74:103–8.
36. Taipale M, et al. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. *Nat Biotechnol*. 2013;31(7):630–7.
37. Hutt DM, Powers ET, Balch WE. The proteostasis boundary in misfolding diseases of membrane traffic. *FEBS Lett*. 2009;583(16):2639–46.
38. Bouchecareilh M, Conkright JJ, Balch WE. Proteostasis strategies for restoring alpha1-antitrypsin deficiency. *Proc Am Thorac Soc*. 2010;7(6):415–22.
39. Goopu B, Lomas DA. Conformational pathology of the serpins: themes, variations, and therapeutic strategies. *Annu Rev Biochem*. 2009;78:147–76.
40. Goopu B, Dickens JA, Lomas DA. The molecular and cellular pathology of alpha(1)-antitrypsin deficiency. *Trends Mol Med*. 2014;20(2):116–27.
41. Teckman JH. Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy. *COPD*. 2013;10 Suppl 1:35–43.
42. Wang Y, Perlmuter DH. Targeting intracellular degradation pathways for treatment of liver disease caused by alpha1-antitrypsin deficiency. *Pediatr Res*. 2014;75(1–2):133–9.
43. Perlmuter DH. Alpha-1-antitrypsin deficiency: importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates. *Annu Rev Med*. 2011;62:333–45.
44. Marciniak SJ, Lomas DA. Genetic susceptibility. *Clin Chest Med*. 2014;35(1):29–38.
45. Kueppers F, Bearn AG. A possible experimental approach to the association of hereditary alpha-1-antitrypsin deficiency and pulmonary emphysema. *Proc Soc Exp Biol Med*. 1966;121(4):1207–9.
46. Turino GM, et al. Serum elastase inhibitor deficiency and alpha 1-antitrypsin deficiency in patients with obstructive emphysema. *Science*. 1969;165(3894):709–11.
47. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. *N Engl J Med*. 1976;294(24):1316–21.
48. Silverman EK, et al. Alpha-1-antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening. *Am Rev Respir Dis*. 1989;140(4):961–6.

49. Dyaico MJ, et al. Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model. *Science*. 1988;242(4884):1409–12.
50. Sharp HL, et al. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. *J Lab Clin Med*. 1969;73(6):934–9.
51. Carlson JA, et al. Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice. *J Clin Invest*. 1989;83(4):1183–90.
52. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. *N Engl J Med*. 1986;314(12):736–9.
53. Tan L, et al. Circulating polymers in alpha1-antitrypsin deficiency. *Eur Respir J*. 2014;43(5):1501–4.
54. Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. *J Clin Invest*. 1990;85(5):1343–52.
55. Stockley RA, Mannino D, Barnes PJ. Burden and pathogenesis of chronic obstructive pulmonary disease. *Proc Am Thorac Soc*. 2009;6(6):524–6.
56. Goopu B, Ekeowa UI, Lomas DA. Mechanisms of emphysema in alpha1-antitrypsin deficiency: molecular and cellular insights. *Eur Respir J*. 2009;34(2):475–88.
57. Lomas DA, et al. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. *Nature*. 1992;357(6379):605–7.
58. Lomas DA, et al. Effect of the Z mutation on the physical and inhibitory properties of alpha 1-antitrypsin. *Biochemistry*. 1993;32(2):500–8.
59. Kim D, Yu MH. Folding pathway of human alpha 1-antitrypsin: characterization of an intermediate that is active but prone to aggregation. *Biochem Biophys Res Commun*. 1996;226(2):378–84.
60. James EL, et al. Probing the unfolding pathway of alpha1-antitrypsin. *J Biol Chem*. 1999;274(14):9482–8.
61. Krishnan B, Gierasch LM. Dynamic local unfolding in the serpin alpha-1 antitrypsin provides a mechanism for loop insertion and polymerization. *Nat Struct Mol Biol*. 2011;18(2):222–6.
62. Ekeowa UI, et al. Defining the mechanism of polymerization in the serpinopathies. *Proc Natl Acad Sci U S A*. 2010;107(40):17146–51.
63. Gettins PG. Serpin structure, mechanism, and function. *Chem Rev*. 2002;102(12):4751–804.
64. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. *Nature*. 2000;407(6806):923–6.
65. Yu MH, Lee KN, Kim J. The Z type variation of human alpha 1-antitrypsin causes a protein folding defect. *Nat Struct Biol*. 1995;2(5):363–7.
66. Dafforn TR, et al. A kinetic mechanism for the polymerization of alpha1-antitrypsin. *J Biol Chem*. 1999;274(14):9548–55.
67. Lomas DA. Twenty years of polymers: a personal perspective on alpha-1 antitrypsin deficiency. *COPD*. 2013;10 Suppl 1:17–25.
68. Nyon MP, et al. Structural dynamics associated with intermediate formation in an archetypal conformational disease. *Structure*. 2012;20(3):504–12.
69. Yamasaki M, et al. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. *Nature*. 2008;455(7217):1255–8.
70. Yamasaki M, et al. Molecular basis of alpha1-antitrypsin deficiency revealed by the structure of a domain-swapped trimer. *EMBO Rep*. 2011;12(10):1011–7.
71. Ou WJ, et al. Association of folding intermediates of glycoproteins with calnexin during protein maturation. *Nature*. 1993;364(6440):771–6.
72. Schmidt BZ, Perlmuter DH. Grp78, Grp94, and Grp170 interact with alpha1-antitrypsin mutants that are retained in the endoplasmic reticulum. *Am J Physiol Gastrointest Liver Physiol*. 2005;289(3):G444–55.
73. Papp E, et al. Changes of endoplasmic reticulum chaperone complexes, redox state, and impaired protein disulfide reductase activity in misfolding alpha1-antitrypsin transgenic mice. *FASEB J*. 2006;20(7):1018–20.

74. Nyfeler B, et al. Identification of ERGIC-53 as an intracellular transport receptor of alpha1-antitrypsin. *J Cell Biol.* 2008;180(4):705–12.
75. Sifers RN. Intracellular processing of alpha1-antitrypsin. *Proc Am Thorac Soc.* 2010; 7(6):376–80.
76. Stagg SM, LaPointe P, Balch WE. Structural design of cage and coat scaffolds that direct membrane traffic. *Curr Opin Struct Biol.* 2007;17(2):221–8.
77. Miller EA, Schekman R. COPII – a flexible vesicle formation system. *Curr Opin Cell Biol.* 2013;25(4):420–7.
78. Brandizzi F, Barlowe C. Organization of the ER-Golgi interface for membrane traffic control. *Nat Rev Mol Cell Biol.* 2013;14(6):382–92.
79. Routledge KE, Gupta V, Balch WE. Emergent properties of proteostasis-COPII coupled systems in human health and disease. *Mol Membr Biol.* 2010;27(8):385–97.
80. Cabral CM, et al. Organizational diversity among distinct glycoprotein endoplasmic reticulum-associated degradation programs. *Mol Biol Cell.* 2002;13(8):2639–50.
81. Le A, et al. Association between calnexin and a secretion-incompetent variant of human alpha 1-antitrypsin. *J Biol Chem.* 1994;269(10):7514–9.
82. Wu Y, et al. A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. *Proc Natl Acad Sci U S A.* 1994;91(19):9014–8.
83. Qu D, et al. Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. *J Biol Chem.* 1996;271(37):22791–5.
84. Choudhury P, et al. Intracellular association between UDP-glucose:glycoprotein glucosyltransferase and an incompletely folded variant of alpha1-antitrypsin. *J Biol Chem.* 1997;272(20):13446–51.
85. Cabral CM, et al. Processing by endoplasmic reticulum mannosidases partitions a secretion-impaired glycoprotein into distinct disposal pathways. *J Biol Chem.* 2000;275(32):25015–22.
86. Wu Y, et al. Elucidation of the molecular logic by which misfolded alpha 1-antitrypsin is preferentially selected for degradation. *Proc Natl Acad Sci U S A.* 2003;100(14):8229–34.
87. Ferris SP, et al. UDP-glucose:glycoprotein glucosyltransferase (UGGT1) promotes substrate solubility in the endoplasmic reticulum. *Mol Biol Cell.* 2013;24(17):2597–608.
88. Teckman JH, Gilmore R, Perlmuter DH. Role of ubiquitin in proteasomal degradation of mutant alpha(1)-antitrypsin Z in the endoplasmic reticulum. *Am J Physiol Gastrointest Liver Physiol.* 2000;278(1):G39–48.
89. Pan S, et al. Golgi localization of ERMAnI defines spatial separation of the mammalian glycoprotein quality control system. *Mol Biol Cell.* 2011;22(16):2810–22.
90. Kamimoto T, et al. Intracellular inclusions containing mutant alpha1-antitrypsin Z are propagated in the absence of autophagic activity. *J Biol Chem.* 2006;281(7):4467–76.
91. Hidvegi T, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. *Science.* 2010;329(5988):229–32.
92. Kruse KB, Brodsky JL, McCracken AA. Characterization of an ERAD gene as VPS30/ATG6 reveals two alternative and functionally distinct protein quality control pathways: one for soluble Z variant of human alpha-1 proteinase inhibitor (A1PiZ) and another for aggregates of A1PiZ. *Mol Biol Cell.* 2006;17(1):203–12.
93. Schuck S, Gallagher CM, Walter P. ER-phagy mediates selective degradation of endoplasmic reticulum independently of the core autophagy machinery. *J Cell Sci.* 2014;127(Pt 18):4078–88.
94. Bernales S, Schuck S, Walter P. ER-phagy: selective autophagy of the endoplasmic reticulum. *Autophagy.* 2007;3(3):285–7.
95. Long OS, et al. A *C. elegans* model of human alpha1-antitrypsin deficiency links components of the RNAi pathway to misfolded protein turnover. *Hum Mol Genet.* 2014;23(19):5109–22.

96. Chu AS, Perlmutter DH, Wang Y. Capitalizing on the autophagic response for treatment of liver disease caused by alpha-1-antitrypsin deficiency and other genetic diseases. *Biomed Res Int.* 2014;2014:459823.
97. Teckman JH, Jain A. Advances in alpha-1-antitrypsin deficiency liver disease. *Curr Gastroenterol Rep.* 2014;16(1):367.
98. Pan S, et al. Single nucleotide polymorphism-mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in alpha1-antitrypsin deficiency. *Hepatology.* 2009;50(1):275–81.
99. Rab A, et al. Cigarette smoke and CFTR: implications in the pathogenesis of COPD. *Am J Physiol Lung Cell Mol Physiol.* 2013;305(8):L530–41.
100. Carp H, Janoff A. Possible mechanisms of emphysema in smokers. In vitro suppression of serum elastase-inhibitory capacity by fresh cigarette smoke and its prevention by antioxidants. *Am Rev Respir Dis.* 1978;118(3):617–21.
101. Taggart C, et al. Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. *J Biol Chem.* 2000;275(35):27258–65.
102. McElvaney NG, Greene CM. Mechanisms of protein misfolding in conformational lung diseases. *Curr Mol Med.* 2012;12(7):850–9.
103. Tudor RM, Janciauskiene SM, Petrache I. Lung disease associated with alpha1-antitrypsin deficiency. *Proc Am Thorac Soc.* 2010;7(6):381–6.
104. Alam S, et al. Oxidation of Z alpha1-antitrypsin by cigarette smoke induces polymerization: a novel mechanism of early-onset emphysema. *Am J Respir Cell Mol Biol.* 2011;45(2):261–9.
105. Alam S, et al. Z alpha1-antitrypsin confers a proinflammatory phenotype that contributes to chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2014;189(8):909–31.
106. Lockett AD, et al. Active trafficking of alpha 1 antitrypsin across the lung endothelium. *PLoS One.* 2014;9(4):e93979.
107. Li Z, et al. Oxidized {alpha}1-antitrypsin stimulates the release of monocyte chemotactic protein-1 from lung epithelial cells: potential role in emphysema. *Am J Physiol Lung Cell Mol Physiol.* 2009;297(2):L388–400.
108. Burns AR, Smith CW, Walker DC. Unique structural features that influence neutrophil emigration into the lung. *Physiol Rev.* 2003;83(2):309–36.
109. Kao RC, et al. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. *J Clin Invest.* 1988;82(6):1963–73.
110. Sindén NJ, Stockley RA. Proteinase 3 activity in sputum from subjects with alpha-1-antitrypsin deficiency and COPD. *Eur Respir J.* 2013;41(5):1042–50.
111. Churg A, Zhou S, Wright JL. Series “matrix metalloproteinases in lung health and disease”: matrix metalloproteinases in COPD. *Eur Respir J.* 2012;39(1):197–209.
112. Lesser M, Padilla ML, Cardozo C. Induction of emphysema in hamsters by intratracheal instillation of cathepsin B. *Am Rev Respir Dis.* 1992;145(3):661–8.
113. Ekeowa UI, Marciniak SJ, Lomas DA. Alpha(1)-antitrypsin deficiency and inflammation. *Expert Rev Clin Immunol.* 2011;7(2):243–52.
114. Sohrab S, et al. Mechanism of alpha-1 antitrypsin endocytosis by lung endothelium. *FASEB J.* 2009;23(9):3149–58.
115. Paakko P, et al. Activated neutrophils secrete stored alpha 1-antitrypsin. *Am J Respir Crit Care Med.* 1996;154(6 Pt 1):1829–33.
116. Cohen AB. Interrelationships between the human alveolar macrophage and alpha-1-antitrypsin. *J Clin Invest.* 1973;52(11):2793–9.
117. Cichy J, Potempa J, Travis J. Biosynthesis of alpha1-proteinase inhibitor by human lung-derived epithelial cells. *J Biol Chem.* 1997;272(13):8250–5.
118. Venembre P, et al. Secretion of alpha 1-antitrypsin by alveolar epithelial cells. *FEBS Lett.* 1994;346(2–3):171–4.
119. Geraghty P, et al. Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. *J Immunol.* 2007;178(9):5871–8.

120. Houghton AM, et al. Elastin fragments drive disease progression in a murine model of emphysema. *J Clin Invest.* 2006;116(3):753–9.
121. Hubbard RC, et al. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B₄ by alveolar macrophages. *J Clin Invest.* 1991;88(3):891–7.
122. Nakamura H, et al. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. *J Clin Invest.* 1992;89(5):1478–84.
123. Woolhouse IS, Bayley DL, Stockley RA. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8. *Thorax.* 2002;57(8):709–14.
124. Carroll TP, et al. Evidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiency. *J Immunol.* 2010;184(8):4538–46.
125. Elliott PR, Bilton D, Lomas DA. Lung polymers in Z alpha1-antitrypsin deficiency-related emphysema. *Am J Respir Cell Mol Biol.* 1998;18(5):670–4.
126. Mulgrew AT, et al. Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. *Chest.* 2004;125(5):1952–7.
127. Parmar JS, et al. Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. *Am J Respir Cell Mol Biol.* 2002;26(6):723–30.
128. Miyata Y, Nakamoto H, Neckers L. The therapeutic target Hsp90 and cancer hallmarks. *Curr Pharm Des.* 2013;19(3):347–65.
129. Pratt WB, et al. Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. *Annu Rev Pharmacol Toxicol.* 2015;55:353–71.
130. van Oosten-Hawle P, Porter RS, Morimoto RI. Regulation of organismal proteostasis by transcellular chaperone signaling. *Cell.* 2013;153(6):1366–78.
131. van Oosten-Hawle P, Morimoto RI. Transcellular chaperone signaling: an organismal strategy for integrated cell stress responses. *J Exp Biol.* 2014;217(Pt 1):129–36.
132. Silva MC, Amaral MD, Morimoto RI. Neuronal reprogramming of protein homeostasis by calcium-dependent regulation of the heat shock response. *PLoS Genet.* 2013;9(8):e1003711.
133. Darwin C. On the origin of species by means of natural selection, vol. 1. London: J. Murray; 1859. 502 p.
134. Dickens JA, Lomas DA. Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis. *Drug Des Devel Ther.* 2011;5:391–405.
135. Turner AM. Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies. *BioDrugs.* 2013;27(6):547–58.
136. Turner AM. Fifty years on: GWAS confirms the role of a rare variant in lung disease. *PLoS Genet.* 2013;9(8):e1003768.
137. Thun GA, et al. Causal and synthetic associations of variants in the SERPINA gene cluster with alpha1-antitrypsin serum levels. *PLoS Genet.* 2013;9(8):e1003585.
138. Wiseman RL, et al. Protein energetics in maturation of the early secretory pathway. *Curr Opin Cell Biol.* 2007;19(4):359–67.
139. Wiseman RL, et al. An adaptable standard for protein export from the endoplasmic reticulum. *Cell.* 2007;131(4):809–21.
140. Wiseman RL, Balch WE. A new pharmacology – drugging stressed folding pathways. *Trends Mol Med.* 2005;11(8):347–50.
141. Powers ET, Powers DL, Gierasch LM. FoldEco: a model for proteostasis in *E. coli*. *Cell Rep.* 2012;1(3):265–76.
142. Rudnick DA, et al. Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency. *Hepatology.* 2006;44(4):976–82.
143. Tyedmers J, Mogk A, Bukau B. Cellular strategies for controlling protein aggregation. *Nat Rev Mol Cell Biol.* 2010;11(11):777–88.

144. Winkler J, et al. Chaperone networks in protein disaggregation and prion propagation. *J Struct Biol.* 2012;179(2):152–60.
145. Gosai SJ, et al. Automated high-content live animal drug screening using *C. elegans* expressing the aggregation prone serpin alpha1-antitrypsin Z. *PLoS One.* 2010;5(11):e15460.
146. Li J, et al. Fluphenazine reduces proteotoxicity in *C. elegans* and mammalian models of alpha-1-antitrypsin deficiency. *PLoS One.* 2014;9(1):e87260.
147. O'Reilly LP, et al. A genome-wide RNAi screen identifies potential drug targets in a *C. elegans* model of alpha1-antitrypsin deficiency. *Hum Mol Genet.* 2014;23(19):5123–32.
148. Hidvegi T, et al. Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response. *J Biol Chem.* 2005;280(47):39002–15.
149. Ordonez A, et al. Endoplasmic reticulum polymers impair luminal protein mobility and sensitize to cellular stress in alpha1-antitrypsin deficiency. *Hepatology.* 2013;57(5):2049–60.
150. Lawless MW, et al. Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. *J Immunol.* 2004;172(9):5722–6.
151. Lomas DA, et al. Hypersensitive mousetraps, alpha1-antitrypsin deficiency and dementia. *Biochem Soc Trans.* 2002;30(2):89–92.
152. Liu Y, Chang A. Heat shock response relieves ER stress. *EMBO J.* 2008;27(7):1049–59.
153. Marcus NY, et al. Oxidative stress contributes to liver damage in a murine model of alpha-1-antitrypsin deficiency. *Exp Biol Med (Maywood).* 2012;237(10):1163–72.
154. Pahl HL, Baerle PA. The ER-overload response: activation of NF-kappa B. *Trends Biochem Sci.* 1997;22(2):63–7.
155. Wewers MD, Crystal RG. Alpha-1 antitrypsin augmentation therapy. *COPD.* 2013;10 Suppl 1:64–7.
156. Stockley RA, Miravittles M, Vogelmeier C. Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. *Orphanet J Rare Dis.* 2013;8:149.
157. Sabina J, Tobias W. Augmentation therapy with alpha1-antitrypsin: novel perspectives. *Cardiovasc Hematol Disord Drug Targets.* 2013;13(2):90–8.
158. Mohanka M, Khemasuwan D, Stoller JK. A review of augmentation therapy for alpha-1 antitrypsin deficiency. *Expert Opin Biol Ther.* 2012;12(6):685–700.
159. Kueppers F. The role of augmentation therapy in alpha-1 antitrypsin deficiency. *Curr Med Res Opin.* 2011;27(3):579–88.
160. Gadek JE, et al. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. *J Clin Invest.* 1981;68(5):1158–65.
161. Wewers MD, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. *N Engl J Med.* 1987;316(17):1055–62.
162. Tonelli AR, Brantly ML. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies. *Ther Adv Respir Dis.* 2010;4(5):289–312.
163. Seersholm N, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. *Eur Respir J.* 1997;10(10):2260–3.
164. Wencker M, et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. *Chest.* 2001;119(3):737–44.
165. Tonelli AR, et al. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the alpha-1 foundation DNA and tissue bank. *Int J Chron Obstruct Pulmon Dis.* 2009;4:443–52.
166. Ghouse R, et al. Mysteries of alpha1-antitrypsin deficiency: emerging therapeutic strategies for a challenging disease. *Dis Model Mech.* 2014;7(4):411–9.
167. Loring HS, Flotte TR. Current status of gene therapy for alpha-1 antitrypsin deficiency. *Expert Opin Biol Ther.* 2015;15(3):329–36.

168. Mueller C, Flotte TR. Gene-based therapy for alpha-1 antitrypsin deficiency. *COPD*. 2013;10 Suppl 1:44–9.
169. Haq I, et al. Reactive centre loop mutants of alpha-1-antitrypsin reveal position-specific effects on intermediate formation along the polymerization pathway. *Biosci Rep*. 2013;33(3):e00046.
170. Patschull AO, et al. Therapeutic target-site variability in alpha1-antitrypsin characterized at high resolution. *Acta Crystallogr Sect F: Struct Biol Cryst Commun*. 2011;67(Pt 12):1492–7.
171. Patschull AO, et al. In silico assessment of potential druggable pockets on the surface of alpha1-antitrypsin conformers. *PLoS One*. 2012;7(5):e36612.
172. Fra AM, et al. Three new alpha1-antitrypsin deficiency variants help to define a C-terminal region regulating conformational change and polymerization. *PLoS One*. 2012;7(6):e38405.
173. Pastore N, Ballabio A, Brunetti-Pierri N. Autophagy master regulator TFEB induces clearance of toxic SERPINA1/alpha-1-antitrypsin polymers. *Autophagy*. 2013;9(7):1094–6.
174. Teckman J, et al. Appropriateness of newborn screening for alpha1-antitrypsin deficiency. *J Pediatr Gastroenterol Nutr*. 2014;58(2):199–203.
175. Akerfelt M, Morimoto RI, Sistonen L. Heat shock factors: integrators of cell stress, development and lifespan. *Nat Rev Mol Cell Biol*. 2010;11(8):545–55.
176. Ellis RJ, van der Vies SM. Molecular chaperones. *Annu Rev Biochem*. 1991;60:321–47.
177. Tsai B, et al. Protein disulfide isomerase acts as a redox-dependent chaperone to unfold cholera toxin. *Cell*. 2001;104(6):937–48.
178. Weber-Ban EU, et al. Global unfolding of a substrate protein by the Hsp100 chaperone ClpA. *Nature*. 1999;401(6748):90–3.
179. Brodsky JL, et al. The requirement for molecular chaperones during endoplasmic reticulum-associated protein degradation demonstrates that protein export and import are mechanistically distinct. *J Biol Chem*. 1999;274(6):3453–60.
180. Meacham GC, et al. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. *Nat Cell Biol*. 2001;3(1):100–5.
181. Assimon VA, et al. Hsp70 protein complexes as drug targets. *Curr Pharm Des*. 2013;19(3):404–17.
182. Patury S, Miyata Y, Gestwicki JE. Pharmacological targeting of the Hsp70 chaperone. *Curr Top Med Chem*. 2009;9(15):1337–51.
183. Zuiderweg ER, et al. Allostery in the Hsp70 chaperone proteins. *Top Curr Chem*. 2013;328:99–153.
184. Alarcon SV, et al. Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy. *Curr Mol Med*. 2012;12(9):1125–41.
185. Zelin E, et al. The p23 molecular chaperone and GCN5 acetylase jointly modulate protein-DNA dynamics and open chromatin status. *Mol Cell*. 2012;48(3):459–70.
186. Tariq M, et al. Trithorax requires Hsp90 for maintenance of active chromatin at sites of gene expression. *Proc Natl Acad Sci U S A*. 2009;106(4):1157–62.
187. Minet E, et al. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. *FEBS Lett*. 1999;460(2):251–6.
188. Sepehrnia B, et al. Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. *J Biol Chem*. 1996;271(25):15084–90.
189. DeZwaan DC, Freeman BC. HSP90 manages the ends. *Trends Biochem Sci*. 2010;35(7):384–91.
190. Wilkinson DS, Taylor RC, Dillin A. Analysis of aging in *Caenorhabditis elegans*. *Methods Cell Biol*. 2012;107:353–81.
191. Dillin A, Gottschling DE, Nystrom T. The good and the bad of being connected: the integrons of aging. *Curr Opin Cell Biol*. 2014;26:107–12.
192. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. *Nat Rev Cancer*. 2005;5(10):761–72.

193. Liang P, MacRae TH. Molecular chaperones and the cytoskeleton. *J Cell Sci.* 1997;110(Pt 13):1431–40.
194. Wettstein G, et al. Small heat shock proteins and the cytoskeleton: an essential interplay for cell integrity? *Int J Biochem Cell Biol.* 2012;44(10):1680–6.
195. Ellgaard L, Helenius A. Quality control in the endoplasmic reticulum. *Nat Rev Mol Cell Biol.* 2003;4(3):181–91.
196. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. *Nat Rev Mol Cell Biol.* 2007;8(7):519–29.
197. Sekijima Y, et al. The biological and chemical basis for tissue-selective amyloid disease. *Cell.* 2005;121(1):73–85.
198. Lindquist SL, Kelly JW. Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. *Cold Spring Harb Perspect Biol.* 2011;3:a004507.
199. Nyon MP, Gooptu B. Therapeutic targeting of misfolding and conformational change in alpha1-antitrypsin deficiency. *Future Med Chem.* 2014;6(9):1047–65.
200. Dersh D, et al. OS-9 facilitates turnover of nonnative GRP94 marked by hyperglycosylation. *Mol Biol Cell.* 2014;25(15):2220–34.
201. Roussel BD, et al. Unravelling the twists and turns of the serpinopathies. *FEBS J.* 2011;278(20):3859–67.
202. Bouche-careilh M, et al. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of alpha1-antitrypsin deficiency. *J Biol Chem.* 2012; 287(45):38265–78.
203. Coppinger JA, et al. A chaperone trap contributes to the onset of cystic fibrosis. *PLoS One.* 2012;7(5):e37682.
204. Kampinga HH, Craig EA. The HSP70 chaperone machinery: J proteins as drivers of functional specificity. *Nat Rev Mol Cell Biol.* 2010;11(8):579–92.
205. Dudek J, et al. Functions and pathologies of BiP and its interaction partners. *Cell Mol Life Sci.* 2009;66(9):1556–69.
206. Otero JH, Lizak B, Hendershot LM. Life and death of a BiP substrate. *Semin Cell Dev Biol.* 2010;21(5):472–8.
207. Wang XY, Subjeck JR. High molecular weight stress proteins: identification, cloning and utilisation in cancer immunotherapy. *Int J Hyperthermia.* 2013;29(5):364–75.
208. Ni M, Lee AS. ER chaperones in mammalian development and human diseases. *FEBS Lett.* 2007;581(19):3641–51.
209. Kakkar V, Prins LC, Kampinga HH. DNAJ proteins and protein aggregation diseases. *Curr Top Med Chem.* 2012;12(22):2479–90.
210. Evans CG, Chang L, Gestwicki JE. Heat shock protein 70 (hsp70) as an emerging drug target. *J Med Chem.* 2010;53(12):4585–602.
211. Nishikawa S, Brodsky JL, Nakatsukasa K. Roles of molecular chaperones in endoplasmic reticulum (ER) quality control and ER-associated degradation (ERAD). *J Biochem.* 2005;137(5):551–5.
212. Majeski AE, Dice JF. Mechanisms of chaperone-mediated autophagy. *Int J Biochem Cell Biol.* 2004;36(12):2435–44.
213. Chen CY, Balch WE. The Hsp90 chaperone complex regulates GDI-dependent Rab recycling. *Mol Biol Cell.* 2006;17(8):3494–507.
214. Stagg SM, et al. Structural basis for cargo regulation of COPII coat assembly. *Cell.* 2008;134(3):474–84.
215. Gurkan C, et al. The COPII cage: unifying principles of vesicle coat assembly. *Nat Rev Mol Cell Biol.* 2006;7(10):727–38.
216. Stagg SM, et al. Structure of the Sec13/31 COPII coat cage. *Nature.* 2006;439(7073): 234–8.

217. D'Arcangelo JG, Stahmer KR, Miller EA. Vesicle-mediated export from the ER: COPII coat function and regulation. *Biochim Biophys Acta*. 2013;1833(11):2464–72.
218. Zanetti G, et al. COPII and the regulation of protein sorting in mammals. *Nat Cell Biol*. 2012;14(1):20–8.
219. Graef M, et al. ER exit sites are physical and functional core autophagosome biogenesis components. *Mol Biol Cell*. 2013;24(18):2918–31.
220. Ge L, et al. The ER-Golgi intermediate compartment is a key membrane source for the LC3 lipidation step of autophagosome biogenesis. *Elife*. 2013;2:e00947.
221. Tan D, et al. The EM structure of the TRAPP3 complex leads to the identification of a requirement for COPII vesicles on the macroautophagy pathway. *Proc Natl Acad Sci U S A*. 2013;110(48):19432–7.
222. Jackson LP. Structure and mechanism of COPI vesicle biogenesis. *Curr Opin Cell Biol*. 2014;29:67–73.
223. Faini M, et al. Vesicle coats: structure, function, and general principles of assembly. *Trends Cell Biol*. 2013;23(6):279–88.
224. Allan BB, Balch WE. Protein sorting by directed maturation of Golgi compartments. *Science*. 1999;285(5424):63–6.
225. Granell S, et al. Sequestration of mutated alpha1-antitrypsin into inclusion bodies is a cell-protective mechanism to maintain endoplasmic reticulum function. *Mol Biol Cell*. 2008;19(2):572–86.
226. Zuber C, et al. EDEM1 reveals a quality control vesicular transport pathway out of the endoplasmic reticulum not involving the COPII exit sites. *Proc Natl Acad Sci U S A*. 2007;104(11):4407–12.
227. Le Fourn V, et al. Large protein complexes retained in the ER are dislocated by non-COPII vesicles and degraded by selective autophagy. *Cell Mol Life Sci*. 2013;70(11):1985–2002.
228. Anfinsen CB. Principles that govern the folding of protein chains. *Science*. 1973;181(4096):223–30.
229. Jin L, et al. Ubiquitin-dependent regulation of COPII coat size and function. *Nature*. 2012;482(7386):495–500.
230. Fryer LG, et al. The endoplasmic reticulum coat protein II transport machinery coordinates cellular lipid secretion and cholesterol biosynthesis. *J Biol Chem*. 2014;289(7):4244–61.
231. Russo R, Esposito MR, Iolascon A. Inherited hematological disorders due to defects in coat protein (COP)II complex. *Am J Hematol*. 2013;88(2):135–40.
232. Barlowe CK, Miller EA. Secretory protein biogenesis and traffic in the early secretory pathway. *Genetics*. 2013;193(2):383–410.
233. Saito K, et al. TANGO1 facilitates cargo loading at endoplasmic reticulum exit sites. *Cell*. 2009;136(5):891–902.
234. Saito K, et al. cTAGE5 mediates collagen secretion through interaction with TANGO1 at endoplasmic reticulum exit sites. *Mol Biol Cell*. 2011;22(13):2301–8.
235. Reiterer V, Nyfeler B, Hauri HP. Role of the lectin VIP36 in post-ER quality control of human alpha1-antitrypsin. *Traffic*. 2010;11(8):1044–55.
236. Gelling CL, et al. The endosomal protein-sorting receptor sortilin has a role in trafficking alpha-1 antitrypsin. *Genetics*. 2012;192(3):889–903.
237. Freeze HH, Ng BG. Golgi glycosylation and human inherited diseases. *Cold Spring Harb Perspect Biol*. 2011;3(9):a005371.
238. Mattioli F, Sixma TK. Lysine-targeting specificity in ubiquitin and ubiquitin-like modification pathways. *Nat Struct Mol Biol*. 2014;21(4):308–16.
239. Kovacs JJ, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. *Mol Cell*. 2005;18(5):601–7.
240. Marinova Z, et al. Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. *J Neurochem*. 2009;111(4):976–87.

241. Hageman J, et al. A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. *Mol Cell*. 2010;37(3):355–69.
242. Rao R, et al. Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. *Mol Cancer Ther*. 2010;9(4):942–52.
243. Kahali S, et al. Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response. *FASEB J*. 2012;26(6):2437–45.
244. Westerheide SD, et al. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. *Science*. 2009;323(5917):1063–6.
245. Wagner SA, et al. A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. *Mol Cell Proteomics*. 2011;10(10):M111.013284.
246. Gao YS, Hubbert CC, Yao TP. The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. *J Biol Chem*. 2010;285(15):11219–26.
247. Janke C, Bulinski JC. Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions. *Nat Rev Mol Cell Biol*. 2011;12(12):773–86.
248. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. *Nat Rev Drug Discov*. 2014;13(9):673–91.
249. Hutt DM, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. *Nat Chem Biol*. 2010;6(1):25–33.
250. Lu J, et al. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. *Proc Natl Acad Sci U S A*. 2011;108(52):21200–5.
251. Moresi V, et al. Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. *Cell*. 2010;143(1):35–45.
252. Helquist P, et al. Treatment of Niemann – pick type C disease by histone deacetylase inhibitors. *Neurotherapeutics*. 2013;10(4):688–97.
253. Pipalia NH, et al. Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. *Proc Natl Acad Sci U S A*. 2011;108(14):5620–5.
254. Coppede F. The potential of epigenetic therapies in neurodegenerative diseases. *Front Genet*. 2014;5:220.
255. Shan B, et al. Quantitative proteomic analysis identifies targets and pathways of a 2-aminobenzamide HDAC inhibitor in Friedreich’s ataxia patient iPSC-derived neural stem cells. *J Proteome Res*. 2014;13(11):4558–66.
256. Jia H, et al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington’s disease. *Neurobiol Dis*. 2012;46(2):351–61.
257. Xu C, et al. Chemical probes identify a role for histone deacetylase 3 in Friedreich’s ataxia gene silencing. *Chem Biol*. 2009;16(9):980–9.
258. Herman D, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia. *Nat Chem Biol*. 2006;2(10):551–8.
259. Chang YP, et al. Targeting serpins in high-throughput and structure-based drug design. *Methods Enzymol*. 2011;501:139–75.
260. Leoni F, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. *Proc Natl Acad Sci U S A*. 2002;99(5):2995–3000.
261. Lin HS, et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. *Br J Pharmacol*. 2007;150(7):862–72.
262. Royce SG, et al. Resveratrol has protective effects against airway remodeling and airway hyperreactivity in a murine model of allergic airways disease. *Pathobiol Aging Age Relat Dis*. 2011;1:7134.
263. Hou X, et al. Histone deacetylase inhibitor regulates the balance of Th17/Treg in allergic asthma. *Clin Respir J*. 2014 [Epub ahead of print].

264. Zhou H, et al. Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization. *Can J Physiol Pharmacol*. 2014;92(10):879–85.
265. Ito K, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. *N Engl J Med*. 2005;352(19):1967–76.
266. Ito K, et al. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. *FASEB J*. 2001;15(6):1110–2.
267. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. *J Allergy Clin Immunol*. 2013;131(3):636–45.
268. Winkler AR, Nocka KN, Williams CM. Smoke exposure of human macrophages reduces HDAC3 activity, resulting in enhanced inflammatory cytokine production. *Pulm Pharmacol Ther*. 2012;25(4):286–92.
269. Isajevs S, et al. Different patterns of lung sirtuin expression in smokers with and without chronic obstructive pulmonary disease. *Medicina (Kaunas)*. 2012;48(10):552–7.
270. Sun Q, et al. Overexpression of response gene to complement 32 (RGC32) promotes cell invasion and induces epithelial-mesenchymal transition in lung cancer cells via the NF-kappaB signaling pathway. *Tumour Biol*. 2013;34(5):2995–3002.
271. Yao H, et al. SIRT1 redresses the imbalance of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase-9 in the development of mouse emphysema and human COPD. *Am J Physiol Lung Cell Mol Physiol*. 2013;305(9):L615–24.
272. Yao H, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. *J Clin Invest*. 2012;122(6):2032–45.
273. Ichikawa T, et al. Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin-induced mouse model of asthma. *Respirology*. 2013;18(2):332–9.
274. Jarosz DF, Taipale M, Lindquist S. Protein homeostasis and the phenotypic manifestation of genetic diversity: principles and mechanisms. *Annu Rev Genet*. 2010;44:189–216.
275. Jarosz DF, Lindquist S. Hsp90 and environmental stress transform the adaptive value of natural genetic variation. *Science*. 2010;330(6012):1820–4.
276. Gershenson A, et al. Energy landscapes of functional proteins are inherently risky. *Nat Chem Biol*. 2014;10(11):884–91.